Page last updated: 2024-12-05

triphenyl phosphite

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7540
CHEMBL ID1875503
SCHEMBL ID13289
MeSH IDM0060977

Synonyms (88)

Synonym
phosclere t 36
p 36 (stabilizer)
phenyl phosphite, (pho)3p
trifenylfosfit
mellite 310
trifenoxyfosfin
advance tpp
nsc43789
nsc-43789
efed
stabilizer p 36
p 36
wln: ropor & or
triphenoxyphosphine
phenyl phosphite
nsc-62219
nsc62219
phosphorous acid, triphenyl ester
triphenyl phosphite ,
101-02-0
inchi=1/c18h15o3p/c1-4-10-16(11-5-1)19-22(20-17-12-6-2-7-13-17)21-18-14-8-3-9-15-18/h1-15
NCGC00091577-01
ai3-07866
brn 1079456
tris(phenoxy)phosphine
weston tpp
nsc 43789
adk stab tpp
sumilizer tpp-r
jp 360
trifenoxyfosfin [czech]
einecs 202-908-4
hsdb 2571
tpp (van)
ccris 4890
tp 1 (plasticizer)
trifenylfosfit [czech]
tpp (plasticizer)
sumilizer ttp-r
triphenyl phosphite, 97%
NCGC00091577-02
NCIOPEN2_007800
phosphorous acid triphenyl ester
T0510
NCGC00091577-04
NCGC00091577-03
9p45grd24x ,
phenyl phosphite ((c6h5o)3p)
ec 202-908-4
unii-9p45grd24x
NCGC00254028-01
cas-101-02-0
tox21_202034
NCGC00259583-01
tox21_300002
dtxsid0026252 ,
dtxcid306252
FT-0689185
AKOS015902569
BP-21353
SCHEMBL13289
doverphos 10
triphenyl phosphite [hsdb]
antioxidant tppi
(pho)3p
triphenylphosphite
p(oc6h5)3
p(oph)3
CHEMBL1875503
doverphos 10-hr
lankromark le65
weston egtpp
triphenyl phosphite, purum, >=97.0% (hplc)
F0001-0051
mfcd00003032
triphelyn phosphite
Q222290
EN300-19163
triphenyl phosphite (tpp)
TPPI
triphenyl phosphite (tppi)
plasticizer triphenyl phosphite
99% triphenyl phosphite
plasticizer tppi
plasticizer tpp
AMY42284
triphenyl phosphite tppi
F86961

Research Excerpts

Overview

Triphenyl phosphite is a weak acetylcholinesterase inhibitor and a type II organophosphorus compound-induced delayed neurotoxic agent.

ExcerptReferenceRelevance
"Triphenyl phosphite (TPP) is a weak acetylcholinesterase inhibitor and a type II organophosphorus compound-induced delayed neurotoxic agent. "( Triphenyl phosphite-induced impairment of spatial alternation learning.
Abou-Donia, MB; Christopher, NC; Levin, ED, 1995
)
3.18

Effects

ExcerptReferenceRelevance
"Triphenyl phosphite (TPP) has been examined extensively in our lab to assess its degenerative effects on the visual pathway of the European ferret. "( A quantitative assessment of TPP-induced delayed neuropathy in the retina and lateral geniculate nucleus of the European ferret (Mustela putorius furo).
Aulerich, RJ; Bursian, SJ; Duke, T; Lipsitz, L; Ramsey, DT; Weber, AJ, 2002
)
1.76

Toxicity

ExcerptReferenceRelevance
" Prior administration of phenylmethylsulfonyl fluoride (PMSF) reduced the incidence of damage to the peripheral nerve of animals dosed with TPP, but did not prevent toxic effects on the cell bodies in the spinal cord or the clinical effects."( Histopathological assessment of triphenyl phosphite neurotoxicity in the hen.
Abou-Donia, MB; Brown, HR; Carrington, CD, 1988
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Prior administration of phenylmethylsulfonyl fluoride (PMSF) reduced the incidence of damage to the peripheral nerve of animals dosed with TPP, but did not prevent toxic effects on the cell bodies in the spinal cord or the clinical effects."( Histopathological assessment of triphenyl phosphite neurotoxicity in the hen.
Abou-Donia, MB; Brown, HR; Carrington, CD, 1988
)
0.56
" A neurotoxic dosing regimen (1184 mg/kg/week, sc, for 2 weeks) inhibited both brain and spinal cord NTE (less than or equal to 40%) only marginally 4 and 48 hr postdosing."( Triphenyl phosphite: in vivo and in vitro inhibition of rat neurotoxic esterase.
Grizzle, TB; Lyerly, D; Padilla, SS, 1987
)
1.72
" Oral doses of TOTP resulted in no detectable clinical signs while injections of TPP resulted in mild ataxia to severe paralysis depending upon the dosage level."( Organophosphorus-induced delayed neurotoxicity: a comparative study of the effects of tri-ortho-tolyl phosphate and triphenyl phosphite on the central nervous system of the Japanese quail.
Bursian, SJ; Tanaka, D; Tobias, C; Varghese, RG, 1995
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency15.21490.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency28.18380.000221.22318,912.5098AID588515
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency67.96230.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency45.49750.003041.611522,387.1992AID1159552; AID1159555
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00790.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency76.95880.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (19.51)18.7374
1990's16 (39.02)18.2507
2000's8 (19.51)29.6817
2010's9 (21.95)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.31 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index62.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.65%)6.00%
Case Studies5 (11.63%)4.05%
Observational0 (0.00%)0.25%
Other36 (83.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]